Does the media refer more to PRGO or SUPN?

In the previous week, Perrigo had 4 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 12 mentions for Perrigo and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.21 beat Perrigo's score of 1.17 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NKTR or PRGO?

In the previous week, Perrigo had 6 more articles in the media than Nektar Therapeutics. MarketBeat recorded 12 mentions for Perrigo and 6 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.19 beat Perrigo's score of 1.17 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRGO or PCRX?

In the previous week, Perrigo had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 12 mentions for Perrigo and 11 mentions for Pacira BioSciences. Perrigo's average media sentiment score of 1.17 beat Pacira BioSciences' score of 0.67 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings and valuation, OMER or PRGO?

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $9.89M 86.62 -$3.35M $0.70 16.91 Perrigo $4.18B 0.33 -$1.43B -$13.10 N/A

Is OMER or PRGO more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Perrigo -43.50% 9.96% 3.90%

Does the media refer more to OMER or PRGO?

In the previous week, Perrigo had 8 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Perrigo and 4 mentions for Omeros. Perrigo's average media sentiment score of 1.17 beat Omeros' score of 0.41 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perrigo 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASMB or PRGO?

In the previous week, Perrigo had 10 more articles in the media than Assembly Biosciences. MarketBeat recorded 12 mentions for Perrigo and 2 mentions for Assembly Biosciences. Perrigo's average media sentiment score of 1.17 beat Assembly Biosciences' score of 0.56 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Perrigo (PRGO) Competitors

$10.09 -0.03 (-0.25%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$10.12 +0.03 (+0.35%)

As of 07/31/2026 07:40 PM Eastern

Compare

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

Should you buy Perrigo stock or one of its competitors? MarketBeat compares Perrigo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Perrigo include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Supernus Pharmaceuticals?

Perrigo (NYSE:PRGO) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Perrigo currently has a consensus target price of $19.33, suggesting a potential upside of 91.70%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 40.79%. Given Perrigo's higher probable upside, equities research analysts clearly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

95.9% of Perrigo shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Perrigo has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Perrigo had 4 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 12 mentions for Perrigo and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.21 beat Perrigo's score of 1.17 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Supernus Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.18B	0.33	-$1.43B	-$13.10	N/A
Supernus Pharmaceuticals	$718.95M	3.60	-$38.55M	-$0.51	N/A

Summary

Supernus Pharmaceuticals beats Perrigo on 11 of the 16 factors compared between the two stocks.

How does Perrigo compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Perrigo (NYSE:PRGO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Perrigo had 6 more articles in the media than Nektar Therapeutics. MarketBeat recorded 12 mentions for Perrigo and 6 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.19 beat Perrigo's score of 1.17 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nektar Therapeutics currently has a consensus target price of $150.00, indicating a potential upside of 112.25%. Perrigo has a consensus target price of $19.33, indicating a potential upside of 91.70%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Perrigo	-43.50%	9.96%	3.90%

Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Nektar Therapeutics has higher earnings, but lower revenue than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	43.24	-$164.08M	-$8.42	N/A
Perrigo	$4.18B	0.33	-$1.43B	-$13.10	N/A

Summary

Nektar Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.

How does Perrigo compare to Pacira BioSciences?

Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.18B	0.33	-$1.43B	-$13.10	N/A
Pacira BioSciences	$726.41M	1.43	$7.03M	$0.12	220.08

In the previous week, Perrigo had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 12 mentions for Perrigo and 11 mentions for Pacira BioSciences. Perrigo's average media sentiment score of 1.17 beat Pacira BioSciences' score of 0.67 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Pacira BioSciences	0.70%	10.24%	5.47%

Perrigo presently has a consensus target price of $19.33, suggesting a potential upside of 91.70%. Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 11.32%. Given Perrigo's higher probable upside, research analysts plainly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Perrigo has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Summary

Pacira BioSciences beats Perrigo on 11 of the 16 factors compared between the two stocks.

How does Perrigo compare to Omeros?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Perrigo	-43.50%	9.96%	3.90%

48.8% of Omeros shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Omeros has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	86.62	-$3.35M	$0.70	16.91
Perrigo	$4.18B	0.33	-$1.43B	-$13.10	N/A

In the previous week, Perrigo had 8 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Perrigo and 4 mentions for Omeros. Perrigo's average media sentiment score of 1.17 beat Omeros' score of 0.41 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Perrigo	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros presently has a consensus target price of $38.00, suggesting a potential upside of 220.95%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 91.70%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts plainly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Omeros beats Perrigo on 12 of the 17 factors compared between the two stocks.

How does Perrigo compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Perrigo (NYSE:PRGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Assembly Biosciences has a net margin of -8.98% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Perrigo	-43.50%	9.96%	3.90%

Assembly Biosciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Assembly Biosciences currently has a consensus price target of $44.00, indicating a potential upside of 75.23%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 91.70%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Perrigo had 10 more articles in the media than Assembly Biosciences. MarketBeat recorded 12 mentions for Perrigo and 2 mentions for Assembly Biosciences. Perrigo's average media sentiment score of 1.17 beat Assembly Biosciences' score of 0.56 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assembly Biosciences has higher earnings, but lower revenue than Perrigo. Assembly Biosciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.52	-$6.12M	-$0.11	N/A
Perrigo	$4.18B	0.33	-$1.43B	-$13.10	N/A

Summary

Assembly Biosciences and Perrigo tied by winning 8 of the 16 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRGO vs. The Competition

Export

Metric	Perrigo	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.40B	$11.71B	$6.86B	$23.66B
Dividend Yield	11.25%	2.72%	2.59%	4.21%
P/E Ratio	-0.77	799.05	282.30	31.00
Price / Sales	0.33	751.29	564.98	81.82
Price / Cash	1.91	14.82	28.60	18.73
Price / Book	0.47	10.36	10.92	4.76
Net Income	-$1.43B	$2.82B	$3.49B	$1.07B
7 Day Performance	-0.84%	-0.13%	-0.64%	-0.34%
1 Month Performance	-8.36%	-3.99%	-5.24%	-0.53%
1 Year Performance	-62.21%	156.16%	61.98%	19.19%

Perrigo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRGO Perrigo	4.4108 of 5 stars	$10.09 -0.2%	$19.33 +91.7%	-62.2%	$1.40B	$4.18B	N/A	8,100	Positive News Upcoming Earnings Dividend Announcement
SUPN Supernus Pharmaceuticals	3.8186 of 5 stars	$46.98 +1.7%	$62.83 +33.7%	+25.7%	$2.68B	$718.95M	N/A	580	Upcoming Earnings Short Interest Decrease
NKTR Nektar Therapeutics	2.9288 of 5 stars	$71.35 +0.9%	$150.00 +110.2%	+207.8%	$2.39B	$55.23M	N/A	220	Positive News
PCRX Pacira BioSciences	2.0478 of 5 stars	$26.47 +2.3%	$29.40 +11.1%	+19.7%	$1.02B	$726.41M	220.60	720	News Coverage Upcoming Earnings
OMER Omeros	2.9882 of 5 stars	$11.34 +15.8%	$38.00 +235.1%	+228.0%	$708.55M	$9.89M	16.20	210	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PRGO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Summary

How does Perrigo compare to Nektar Therapeutics?

Summary

How does Perrigo compare to Pacira BioSciences?

Summary

How does Perrigo compare to Omeros?

Summary

How does Perrigo compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Do analysts recommend PRGO or SUPN?

Do institutionals and insiders hold more shares of PRGO or SUPN?

Which has more volatility & risk, PRGO or SUPN?

Does the media refer more to PRGO or SUPN?

Is PRGO or SUPN more profitable?

Which has preferable valuation and earnings, PRGO or SUPN?

Summary

How does Perrigo compare to Nektar Therapeutics?

Does the media refer more to NKTR or PRGO?

Do insiders & institutionals hold more shares of NKTR or PRGO?

Do analysts recommend NKTR or PRGO?

Is NKTR or PRGO more profitable?

Which has more risk & volatility, NKTR or PRGO?

Which has better valuation & earnings, NKTR or PRGO?

Summary

How does Perrigo compare to Pacira BioSciences?

Which has better earnings & valuation, PRGO or PCRX?

Does the media refer more to PRGO or PCRX?

Do insiders and institutionals hold more shares of PRGO or PCRX?

Is PRGO or PCRX more profitable?

Do analysts rate PRGO or PCRX?

Which has more risk & volatility, PRGO or PCRX?

Summary

How does Perrigo compare to Omeros?

Is OMER or PRGO more profitable?

Do institutionals and insiders hold more shares of OMER or PRGO?

Which has more risk and volatility, OMER or PRGO?

Which has stronger earnings and valuation, OMER or PRGO?

Does the media refer more to OMER or PRGO?

Do analysts rate OMER or PRGO?

Summary

How does Perrigo compare to Assembly Biosciences?

Do institutionals & insiders hold more shares of ASMB or PRGO?

Is ASMB or PRGO more profitable?

Which has more risk and volatility, ASMB or PRGO?

Do analysts prefer ASMB or PRGO?

Does the media prefer ASMB or PRGO?

Which has higher valuation & earnings, ASMB or PRGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools